In a landmark moment for public health on the African continent, South Africa today inaugurated the nationwide rollout of Lenacapavir, a twice-yearly injectable medication designed to prevent HIV transmission. The ceremony, held at Lilian Ngoyi Stadium in Secunda, was led by President Cyril Ramaphosa and Health Minister Dr Aaron Motsoaledi, signaling a major escalation in the country’s decades-long battle against HIV/AIDS.
A Presidential Promise Delivered
The introduction of Lenacapavir fulfills a key commitment President Ramaphosa made during his February 2026 State of the Nation Address. At that time, he announced plans for a “massive rollout” of the six-monthly injection, citing its proven high efficacy in preventing HIV transmission. The Presidency described today’s launch as a groundbreaking initiative that underscores collaborative efforts between government, civil society, the private sector, and international development partners—all united in the goal of ending HIV as a public health threat in South Africa.
Timing and Symbolism
The launch arrives just days after the anniversary of the passing of renowned HIV/AIDS activist Nkosi Johnson, who died on 1 June 2001 at the age of 12. His legacy continues to inspire advocacy and action in the fight against the epidemic. Today’s milestone also builds upon South Africa’s 2010 launch of the world’s largest HIV counselling, testing, and treatment campaign—a foundational effort that has yielded measurable progress.
According to the Department of Health’s 2026 Budget Vote, life expectancy in South Africa has risen to 66.9 years as of 2025, up from 54 years in 2010. Maternal mortality has similarly declined, falling to 89 deaths per 100,000 live births by 2020 from a high of 240 per 100,000 in 2010.
The Current Landscape
Despite these advances, HIV remains a significant public health challenge. Statistics South Africa’s Mid-Year Population Estimates for 2025 indicate that approximately 8.15 million people in the country are living with HIV, representing roughly 12.9% of the total population of 63.1 million. Among adults aged 15 to 49—the demographic most affected—the prevalence rate stands at an estimated 18.1%. Nevertheless, expanded access to treatment and care has contributed to a measurable reduction in HIV- and AIDS-related deaths.
Rollout Strategy and Priority Populations
In his recent Budget Vote address, Minister Motsoaledi confirmed that stocks of Lenacapavir are being distributed to depots and health facilities nationwide. The initial phase will focus on 360 health facilities located in high-burden districts. Priority groups for access include:
- Adolescent girls and young women up to age 24
- Pregnant and breastfeeding mothers
- Female sex workers
- Men who have sex with men
- Transgender individuals
- People who inject drugs
The first consignment of 37,920 doses arrived in South Africa in early April 2026. Lenacapavir is classified as a long-acting antiretroviral drug and functions specifically as an HIV-1 capsid inhibitor.
A Preventive Tool, Not a Vaccine
The Department of Health has clarified that Lenacapavir is a preventive medicine, not a vaccine. Its long-acting formulation offers distinct advantages over daily oral PrEP (pre-exposure prophylaxis), including greater discretion, enhanced convenience, and potentially improved adherence—particularly for individuals who face challenges with daily pill-taking or frequent clinic visits.
The South African National AIDS Council (SANAC), which welcomed the drug’s arrival in April, stated this week that the launch heralds a “new chapter in HIV prevention.”
Regulatory and Global Context
South Africa’s regulatory leadership was affirmed when the South African Health Products Regulatory Authority (SAHPRA) became the first African regulatory body to approve Lenacapavir on 27 October 2025. The World Health Organization (WHO) subsequently included the injectable in its guidelines for HIV prevention, recommending it as an additional prevention option. Notably, WHO guidance indicates that Lenacapavir need not be discontinued during pregnancy or breastfeeding for HIV-negative women at high risk of exposure.
This domestic milestone coincides with heightened global attention on HIV/AIDS. The United Nations General Assembly is scheduled to convene a High-Level Meeting on AIDS on 22–23 June 2026 in New York. Held every five years since 2001, this forum serves as the UN’s primary political mechanism for accountability and commitment in the global HIV response. The 2026 meeting will review progress since the 2021 High-Level Meeting and produce a new UN Political Declaration on HIV and AIDS, with Member States negotiating and considering adoption of the text. South Africa, as a UN Member State, participates actively in these deliberations.
UNAIDS South Africa recently expressed enthusiasm on social media platform X about joining President Ramaphosa, the Department of Health, SANAC, and other stakeholders for today’s launch.
Complementary Initiatives
Lenacapavir’s introduction complements other government-led efforts, including the February 2025 launch of the Close the Gap campaign. Developed in partnership with WHO, UNAIDS, and additional stakeholders, this multi-pronged initiative targets high-burden districts, communities, and health facilities to accelerate South Africa’s HIV response. It places special emphasis on underserved and vulnerable populations—including men, youth, children, and key populations—to improve outcomes and close persistent service gaps.
Looking Ahead
Minister Motsoaledi expressed cautious optimism about the road forward, stating that South Africa is now in a position “where we dare say we can eliminate HIV/AIDS as a public health threat.” He concluded with a call for unified action: “All we have to do is to work hard and work hard together as South Africans motivated and bound together by a common destiny.”
With Lenacapavir now entering the prevention toolkit, South Africa takes a decisive step toward that shared destiny—offering new hope, new options, and renewed momentum in the enduring fight against HIV.
